Oak Ridge Investments LLC Arrowhead Pharmaceuticals, Inc. Transaction History

Oak Ridge Investments LLC

$1.36 Billion
Q2 2025

A detailed history of Oak Ridge Investments LLC transactions in Arrowhead Pharmaceuticals, Inc. stock. As of the latest transaction made, Oak Ridge Investments LLC holds 31,926 shares of ARWR stock, worth $568,282. This represents 0.04% of its overall portfolio holdings.

Number of Shares

31,926

Previous 33,734 5.36%

Holding current value

$568,282

Previous $429,000 17.48%

% of portfolio

0.04%

Previous 0.04%

29 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Jul 25, 2025	SELL	$9.99 - $16.97 $18,061 - $30,681	-1,808 Reduced 5.36%	31,926 $504,000
Q1 2025 May 13, 2025	BUY	$12.74 - $21.53 $10,485 - $17,719	823 Added 2.5%	33,734 $429,000
Q4 2024 Jan 15, 2025	SELL	$17.7 - $26.34 $39,400 - $58,632	-2,226 Reduced 6.34%	32,911 $618,000
Q3 2024 Oct 28, 2024	SELL	$19.36 - $29.54 $28,323 - $43,217	-1,463 Reduced 4.0%	35,137 $680,000
Q2 2024 Jul 16, 2024	SELL	$21.87 - $28.24 $116,610 - $150,575	-5,332 Reduced 12.72%	36,600 $951,000
Q1 2024 May 01, 2024	SELL	$27.21 - $39.48 $46,583 - $67,589	-1,712 Reduced 3.92%	41,932 $1.2 Million
Q4 2023 Jan 16, 2024	SELL	$21.2 - $31.03 $85,372 - $124,957	-4,027 Reduced 8.45%	43,644 $1.34 Million
Q3 2023 Oct 30, 2023	SELL	$26.2 - $36.08 $42,522 - $58,557	-1,623 Reduced 3.29%	47,671 $1.28 Million
Q2 2023 Aug 07, 2023	SELL	$25.16 - $41.38 $41,463 - $68,194	-1,648 Reduced 3.24%	49,294 $1.76 Million
Q1 2023 Apr 14, 2023	SELL	$23.68 - $38.51 $74,781 - $121,614	-3,158 Reduced 5.84%	50,942 $1.29 Million
Q4 2022 Jan 24, 2023	SELL	$28.0 - $40.56 $36,512 - $52,890	-1,304 Reduced 2.35%	54,100 $0
Q3 2022 Nov 08, 2022	SELL	$29.63 - $48.31 $10,785 - $17,584	-364 Reduced 0.65%	55,404 $1.83 Million
Q2 2022 Jul 28, 2022	BUY	$27.79 - $50.61 $529,316 - $963,968	19,047 Added 51.87%	55,768 $1.96 Million
Q1 2022 Apr 22, 2022	SELL	$39.62 - $69.97 $836,100 - $1.48 Million	-21,103 Reduced 36.5%	36,721 $1.69 Million
Q4 2021 Feb 01, 2022	SELL	$58.09 - $82.51 $58,612 - $83,252	-1,009 Reduced 1.72%	57,824 $3.83 Million
Q3 2021 Nov 05, 2021	SELL	$58.38 - $84.96 $104,208 - $151,653	-1,785 Reduced 2.94%	58,833 $3.67 Million
Q2 2021 Jul 30, 2021	SELL	$62.15 - $90.32 $1.54 Million - $2.23 Million	-24,702 Reduced 28.95%	60,618 $5.02 Million
Q1 2021 May 12, 2021	SELL	$61.35 - $90.47 $37.7 Million - $55.6 Million	-614,613 Reduced 87.81%	85,320 $5.66 Million
Q1 2021 May 04, 2021	BUY	$61.35 - $90.47 $37.5 Million - $55.3 Million	611,522 Added 691.68%	699,933 $46.4 Million
Q4 2020 Feb 03, 2021	SELL	$43.82 - $85.37 $950,455 - $1.85 Million	-21,690 Reduced 19.7%	88,411 $6.78 Million
Q3 2020 Nov 12, 2020	SELL	$33.21 - $51.27 $260,731 - $402,520	-7,851 Reduced 6.66%	110,101 $4.74 Million
Q2 2020 Aug 05, 2020	SELL	$26.12 - $43.27 $353,926 - $586,308	-13,550 Reduced 10.3%	117,952 $5.09 Million
Q1 2020 May 13, 2020	SELL	$20.56 - $63.12 $3.03 Million - $9.3 Million	-147,293 Closed	0 $0
Q4 2019 Feb 05, 2020	SELL	$28.14 - $73.01 $3.98 Million - $10.3 Million	-141,291 Reduced 48.96%	147,293 $9.34 Million
Q3 2019 Nov 07, 2019	SELL	$26.26 - $34.86 $397,182 - $527,257	-15,125 Reduced 4.98%	288,584 $8.13 Million
Q2 2019 Aug 14, 2019	SELL	$17.43 - $28.82 $508,241 - $840,362	-29,159 Reduced 8.76%	303,709 $8.05 Million
Q1 2019 May 09, 2019	SELL	$12.05 - $20.18 $25,485 - $42,680	-2,115 Reduced 0.63%	332,868 $6.11 Million
Q4 2018 Feb 11, 2019	SELL	$10.74 - $19.7 $476,759 - $874,502	-44,391 Reduced 11.7%	334,983 $4.16 Million
Q3 2018 Nov 07, 2018	BUY	$14.0 - $20.3 $5.31 Million - $7.7 Million	379,374 New	379,374 $7.27 Million

Others Institutions Holding ARWR

# of Institutions

318

Shares Held

99M

Call Options Held

444K

Put Options Held

568K

View Full List

About ARROWHEAD PHARMACEUTICALS, INC.

Ticker ARWR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 105,849,000
Market Cap $1.88B
Description
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in Phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, w...

More about ARWR

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Oak Ridge Investments LLC, based on Form 13F filings with the SEC.

News

Stay updated on Oak Ridge Investments LLC with notifications on news.

Account

Oak Ridge Investments LLC Arrowhead Pharmaceuticals, Inc. Transaction History